Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA prioritizes quick trials for variant-specific COVID-19 vaccines

By Brian Buntz | February 22, 2021

FDA has released updated guidance detailing its plans to streamline authorization of COVID-19 vaccines adapted to more-infectious variants, such as the U.K. variant B.1.1.7, which is now present in dozens of states.

FDA’s guidance would require such companies to launch small clinical studies similar to those needed for annual flu vaccines.

It also encourages sponsors to test modified vaccines in unvaccinated as well as previously-vaccinated individuals.

“The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants,” said Acting FDA Commissioner Dr. Janet Woodcock in a statement.

Recent data suggest that variant B.1.429, initially found in California, is also more infectious than earlier lineages.

Complicating matters further, B.1.1.7 and B.1.429 have merged in a recombination process to create a new hybrid. Other known transmissible variants have emerged in South Africa and Brazil.

With SARS-CoV-2 variants of concern spreading in the U.S. and elsewhere, vaccine developers Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX), Moderna (NSDQ:MRNA) and others have committed to creating boosters against them.BioNTech CEO Uğur Şahin has said it would take about six weeks to adapt its vaccine to a new variant.

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Coronavirus vaccine
9 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny
Johnson & Johnson
Feds halt J&J COVID-19 vaccine due to blood clot concern
Pfizer-BioNTech
Pfizer asks FDA to authorize its COVID-19 vaccine for younger teens
Johnson & Johnson
EMA begins investigation of J&J COVID-19 vaccine’s blood clotting potential 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards